CDXS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

35.83M

+66.98%

-0.035

-73.08%

14.39M

+90.8%

-0.110

-56%

16.30M

+6.35%

-0.100

-37.5%

Estimates Revision

The market is revising Upward the revenue expectations for Codexis, Inc. (CDXS) for FY2025, with the revenue forecasts being adjusted by 3.19% over the past three months. During the same period, the stock price has changed by -38.81%.

Revenue Estimates for FY2025

Revise Upward

+3.19%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-12.25%

In Past 3 Month

Stock Price

Go Down

-38.81%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast CDXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDXS is 6.00 USD with a low forecast of 2.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.00

Averages

6.00

High

11.00

Current: 0.000

Low

2.00

Averages

6.00

High

11.00

No data

Valuation Metrics

The current forward P/E ratio for Codexis Inc (CDXS.O) is -4.95, compared to its 5-year average forward P/E of -22.18. For a more detailed relative valuation and DCF analysis to assess Codexis Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-22.18

Current PE

-4.95

Overvalued PE

6.26

Undervalued PE

-50.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-15.73

Current EV/EBITDA

-3.70

Overvalued EV/EBITDA

3.66

Undervalued EV/EBITDA

-35.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.33

Current PS

1.73

Overvalued PS

11.20

Undervalued PS

1.47

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CDXS News & Events

Events Timeline

No data

News

7.5

01-07PRnewswire

Codexis Partners with Axolabs to Evaluate RNA Manufacturing Platform

7.5

01-07Newsfilter

Codexis Partners with Axolabs to Enhance RNA Manufacturing with ECO Synthesis Platform

9.5

2025-11-05NASDAQ.COM

Tarsus Pharmaceuticals, Inc. (TARS) Posts Q3 Loss but Exceeds Revenue Projections

People Also Watch

Frequently Asked Questions

What is Codexis Inc (CDXS) stock price today?

The current price of CDXS is 1.64 USD — it has decreased -2.38 % in the last trading day.

What is Codexis Inc (CDXS)'s business?

Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

What is the price predicton of CDXS Stock?

What is Codexis Inc (CDXS)'s revenue for the last quarter?

Codexis Inc revenue for the last quarter amounts to 8.60M USD, decreased -32.98 % YoY.

What is Codexis Inc (CDXS)'s earnings per share (EPS) for the last quarter?

Codexis Inc. EPS for the last quarter amounts to -0.22 USD, decreased -24.14 % YoY.

What changes have occurred in the market's expectations for Codexis Inc (CDXS)'s fundamentals?

How many employees does Codexis Inc (CDXS). have?

Codexis Inc (CDXS) has 188 emplpoyees as of January 10 2026.

What is Codexis Inc (CDXS) market cap?

Today CDXS has the market capitalization of 148.13M USD.